Go back to previous topic
Forum nameGeneral Discussion
Topic subject12/17/2021: Mixed bag still - many unknowns - but bad is trending
Topic URLhttp://board.okayplayer.com/okp.php?az=show_topic&forum=4&topic_id=13448755&mesg_id=13450276
13450276, 12/17/2021: Mixed bag still - many unknowns - but bad is trending
Posted by handle, Fri Dec-17-21 11:57 AM
Omicron five times more likely to re-infect than Delta, study says

https://www.reuters.com/business/healthcare-pharmaceuticals/omicron-five-times-more-likely-reinfect-than-delta-study-says-2021-12-17/

The risk of reinfection with the Omicron coronavirus variant is more than five times higher and it has shown no sign of being milder than Delta, a study by Imperial College London showed, as cases soar across Europe and threaten year-end festivities.

The results were based on UK Health Security Agency and National Health Service data on people who tested positive for COVID-19 in a PCR test in England between Nov. 29 and Dec. 11.

"We find no evidence (for both risk of hospitalisation attendance and symptom status) of Omicron having different severity from Delta," the study said, although it noted that data on hospitalisations remains very limited.

---
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/
Study says previous COVID infection provides little immune help against


---
AstraZeneca therapy works against Omicron; results mixed for Regeneron
https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-says-antibody-therapy-has-lower-potency-against-omicron-2021-12-16/

This is for the prophylactic monoclonal antibody injection Evusheld



---
J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron -study

https://www.reuters.com/business/healthcare-pharmaceuticals/jj-sinopharm-sputnik-v-shots-weaker-against-omicron-study-shows-2021-12-17/